![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1601596
¼¼°èÀÇ ½ÃƼÄݸ° ½ÃÀå : Á¦Ç°, ¿ëµµ, ¿¬·É´ë, À¯Åëä³Î, Áö¿ªº° ¿¹Ãø(-2032³â)Global Citicoline Market Research Report Information by Product by Application, by Age Group by Distribution Channel, by Region Forecast till 2032 |
½ÃƼÄݸ° ½ÃÀå ±Ô¸ð´Â 2023³â 4¾ï 3,000¸¸ ´Þ·¯, 2024³â 4¾ï 8,000¸¸ ´Þ·¯¿¡¼ ¿¹Ãø ±â°£ µ¿¾È CAGR 8.99%·Î 2032³â¿¡´Â 10¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå È®´ëÀÇ ¹è°æ¿¡´Â ÇÇÆ®´Ï½º ¹× ½ºÆ÷Ã÷ ºÐ¾ß ¼ö¿ä Áõ°¡, ÀÎÁö °Ç°¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Àü ¼¼°èÀÎÀÇ ¾ó±¼ ¹Ì¿ë¿¡ ´ëÇÑ ¿¸Á Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.
°í·ÉÈ, ÀÎÁö±â´É °È¿¡ ´ëÇÑ ¿ä±¸, ½Å°æÁúȯ Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Àü »ý¾Ö¿¡ °ÉÃÄ ³ú °Ç°°ú ÀÎÁö±â´ÉÀ» À¯ÁöÇÏ´Â °ÍÀÇ Á߿伺¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀº ÃÖ±Ù ¸î ³âµ¿¾È Å©°Ô º¯ÈÇϰí ÀÖ½À´Ï´Ù. Á¤º¸ Á¢±Ù¼º Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÀÎÁö ±â´É ÀúÇÏ ¹× ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº ½Å°æ Áúȯ¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀÌ ÀÌ·¯ÇÑ º¯È¸¦ °¡Á®¿Ô½À´Ï´Ù.
Áö¿ªº° Àü¸Á
ºÏ¹Ì°¡ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ºÏ¹ÌÀÇ ³ëÀÎ Àα¸ Áõ°¡, ¾ó±¼ ±³Á¤ ¹× °³¼± ¼ö¼úÀÇ º¸ÆíÈ, 1ÀÎ´ç °¡Ã³ºÐ ¼ÒµæÀÌ »ó´çÈ÷ ³ô±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.
¶ÇÇÑ, À¯·´Àº ÀǾàǰ ¹× ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ±¸ÃàµÇ¾î ÀÖ°í, Áö¿ª Àüü°¡ °í·ÉȵǾî ÀÖ¾î ½ÃÀå Á¡À¯À² 2À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ½ºÆäÀÎÀº À¯·´¿¡¼ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, µ¶ÀÏÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº 2024³âºÎÅÍ 2032³â±îÁö »ó´çÇÑ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ÀÎÁö °Ç°¿¡ ´ëÇÑ Áö½ÄÀÌ Áõ°¡ÇÏ°í ½ÃÆ¼Äݸ° º¸ÃæÁ¦ÀÇ ÀÌÁ¡À» ÀÌÇØÇÏ°Ô µÇ¸é¼ ³ªÅ¸³ °á°úÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â Àεµ°¡ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Áß±¹ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°è ½ÃƼÄݸ°(Citicoline) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå Á¤ÀÇ¿Í °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢ ºÎ¹®º°/Áö¿ªº°/ÁÖ¿ä ±¹°¡º° ºÐ¼®, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
Global Citicoline Market Research Report Information by Product (Capsules, Tablets, Powder, Eye Drops, and Injection) by Application (Sports Nutrition, Personal Wellness, Treatment [Glaucoma, Stroke, Alzheimer disease, Channel (pression, and Others]), by Age Group (Pediatric, Adult, and Geriatric) by Distribution Channel (Online Channel, Offline Channel), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
The size of the Citicoline market was estimated at USD 0.43 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 8.99% from 2024 to 2032, from USD 0.48 billion in 2024 to USD 1.04 billion by 2032. The market is expanding due to the growing demand from the fitness and sports sectors, the growing awareness of cognitive health, and the growing desire for facial aesthetics worldwide.
According to the report, the aging population, the need for cognitive enhancement, and the rise in neurological illnesses are the primary drivers of the market's expansion. The public's understanding of the significance of preserving brain health and cognitive function throughout life has significantly changed in recent years. Numerous variables, such as increased information availability, an older population, and growing worries about cognitive decline and neurological disorders like Alzheimer's, are to blame for this change.
Market Segments Insights
Type-wise, the Citicoline market is divided into capsules, tablets, powder, eye drops, and injections.
Sports nutrition, personal wellbeing, and treatment are among the applications that form the basis of the market segmentation. Treatment is further divided into categories such as bipolar depression, Alzheimer's illness, stroke, and glaucoma.
The market for Citicoline is segmented by age group, including geriatric, adult, and Pediatric.
The distribution channel, which encompasses both online and offline channels, provides the basis for market segmentation.
Regional Perspectives
In 2022, the biggest market share was held by the North American citicoline market. This is because the North American region's senior population is growing, facial correction and improvement surgeries are becoming more common, and per capita disposable income is considerable.
Due to a robust pharmaceutical and healthcare infrastructure, as well as an aging population throughout the region, the European citicoline market holds the second-largest market share. Furthermore, the Spanish citicoline market is anticipated to develop at the fastest rate in the European region, while the German citicoline market was said to have the greatest market share.
From 2024 to 2032, the Asia-Pacific citicoline market is anticipated to expand at a substantial rate. This is a result of the Asia-Pacific region's growing knowledge of cognitive health and the possible advantages of citicoline supplementation. Furthermore, the Asia-Pacific citicoline market is anticipated to grow at the fastest rate in India, while the China market is predicted to hold the greatest market share.
Africa, Latin America, and the Middle East make up the rest of the world. A increasing senior population and more awareness of cognitive health are expected to fuel growth in the aforementioned regions' citicoline markets.
Companies like Invision Medi Sciences (India), RPG Life Sciences Ltd (India), CHEMO BIOLOGICAL (India), Century Pharma (India), HARBIN PHARMACEUTICAL GROUP (China), UNION KOREA PHARM CO LTD (South Korea), Kyowa Hakko Bio Co., Ltd (Japan), Vitabiotics Ltd (UK), Grupo Ferrer Internacional, S.A (Spain), and Life Extension (US) are just a few examples.